Mei Qin1, Fei Han2, Jian Wu2, Feng-Xia Gao1, Yuan Li2, De-Xin Yan2, Xue-Mei He3, Yang Long3, Xiao-Ping Tang3, De-Lian Ren1, Yan Gao4, Tian-Yang Dai5. 1. Department of Immunology, Basic Medicine College, South West Medical University, Luzhou, Sichuan, China. 2. Department of Thoracic Surgery, The Affiliated Hospital of Southwest, Medical University, Sichuan, Luzhou, China. 3. Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. 4. Department of Immunology, Basic Medicine College, South West Medical University, Luzhou, Sichuan, China. gaoyan7000@sina.com. 5. Department of Immunology, Basic Medicine College, South West Medical University, Luzhou, Sichuan, China. daitianyang0502@sina.com.
Abstract
BACKGROUND: As an H3K27me3 demethylase and counteracts polycomb-mediated transcription repression, KDM6B has been implicated in the development and malignant progression in various types of cancers. However, its potential roles in esophageal squamous cell carcinoma (ESCC) have not been explored. METHODS: The expression of KDM6B in human ESCC tissues and cell lines was examined using RT-qPCR, immunohistochemical staining and immunoblotting. The effects of KDM6B on the proliferation and metastasis of ESCC were examined using in vitro and in vivo functional tests. RNA-seq and ChIP-seq assay were used to demonstrate the molecular biological mechanism of KDM6B in ESCC. RESULTS: We show that the expression level of KDM6B increased significantly in patients with lymph node metastasis. Furthermore, we confirmed that KDM6B knockdown reduces proliferation and metastasis of ESCC cells, while KDM6B overexpression has the opposite effects. Mechanistically, KDM6B regulates TNFA_SIGNALING_VIA_NFκB signalling pathways, and H3K27me3 binds to the promoter region of C/EBPβ, leading to the promotion of C/EBPβ transcription. Besides, we show that GSK-J4, a chemical inhibitor of KDM6B, markedly inhibits proliferation and metastasis of ESCC cells. CONCLUSIONS: The present study demonstrated that KDM6B promotes ESCC progression by increasing the transcriptional activity of C/EBPβ depending on its H3K27 demethylase activity.
BACKGROUND: As an H3K27me3 demethylase and counteracts polycomb-mediated transcription repression, KDM6B has been implicated in the development and malignant progression in various types of cancers. However, its potential roles in esophageal squamous cell carcinoma (ESCC) have not been explored. METHODS: The expression of KDM6B in human ESCC tissues and cell lines was examined using RT-qPCR, immunohistochemical staining and immunoblotting. The effects of KDM6B on the proliferation and metastasis of ESCC were examined using in vitro and in vivo functional tests. RNA-seq and ChIP-seq assay were used to demonstrate the molecular biological mechanism of KDM6B in ESCC. RESULTS: We show that the expression level of KDM6B increased significantly in patients with lymph node metastasis. Furthermore, we confirmed that KDM6B knockdown reduces proliferation and metastasis of ESCC cells, while KDM6B overexpression has the opposite effects. Mechanistically, KDM6B regulates TNFA_SIGNALING_VIA_NFκB signalling pathways, and H3K27me3 binds to the promoter region of C/EBPβ, leading to the promotion of C/EBPβ transcription. Besides, we show that GSK-J4, a chemical inhibitor of KDM6B, markedly inhibits proliferation and metastasis of ESCC cells. CONCLUSIONS: The present study demonstrated that KDM6B promotes ESCC progression by increasing the transcriptional activity of C/EBPβ depending on its H3K27 demethylase activity.
Authors: Sunhwa Hong; Young-Wook Cho; Li-Rong Yu; Hong Yu; Timothy D Veenstra; Kai Ge Journal: Proc Natl Acad Sci U S A Date: 2007-11-14 Impact factor: 11.205
Authors: Jindan Yu; Jianjun Yu; Daniel R Rhodes; Scott A Tomlins; Xuhong Cao; Guoan Chen; Rohit Mehra; Xiaoju Wang; Debashis Ghosh; Rajal B Shah; Sooryanarayana Varambally; Kenneth J Pienta; Arul M Chinnaiyan Journal: Cancer Res Date: 2007-11-15 Impact factor: 12.701
Authors: Yongkun Wei; Weiya Xia; Zhihong Zhang; Jinsong Liu; Huamin Wang; Nazmi V Adsay; Constance Albarracin; Dihua Yu; James L Abbruzzese; Gordon B Mills; Robert C Bast; Gabriel N Hortobagyi; Mien-Chie Hung Journal: Mol Carcinog Date: 2008-09 Impact factor: 4.784
Authors: Sylvia Erhardt; I-Hsin Su; Robert Schneider; Sheila Barton; Andrew J Bannister; Laura Perez-Burgos; Thomas Jenuwein; Tony Kouzarides; Alexander Tarakhovsky; M Azim Surani Journal: Development Date: 2003-09 Impact factor: 6.868
Authors: Yun Zhang; Katherine M Weh; Connor L Howard; Jean-Jack Riethoven; Jennifer L Clarke; Kiran H Lagisetty; Jules Lin; Rishindra M Reddy; Andrew C Chang; David G Beer; Laura A Kresty Journal: Mol Ther Nucleic Acids Date: 2022-08-17 Impact factor: 10.183